U.S. Markets open in 6 hrs 25 mins

Did You Miss Amedisys’s (NASDAQ:AMED) Whopping 723% Share Price Gain?

Simply Wall St

It might be of some concern to shareholders to see the Amedisys, Inc. (NASDAQ:AMED) share price down 11% in the last month. But over five years returns have been remarkably great. In fact, during that period, the share price climbed 723%. Impressive! So it might be that some shareholders are taking profits after good performance. Of course what matters most is whether the business can improve itself sustainably, thus justifying a higher price.

It really delights us to see such great share price performance for investors.

Check out our latest analysis for Amedisys

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During the five years of share price growth, Amedisys moved from a loss to profitability. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

NasdaqGS:AMED Past and Future Earnings, March 17th 2019

We know that Amedisys has improved its bottom line over the last three years, but what does the future have in store? This free interactive report on Amedisys’s balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

It’s nice to see that Amedisys shareholders have received a total shareholder return of 96% over the last year. That gain is better than the annual TSR over five years, which is 52%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. Before spending more time on Amedisys it might be wise to click here to see if insiders have been buying or selling shares.

We will like Amedisys better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.